William G. Wierda

William Wierda is a world-leading CLL clinician-investigator who has contributed to development of virtually every major CLL therapy over the past two decades. He led pivotal studies establishing venetoclax-based fixed-duration regimens in both treatment-naive and relapsed/refractory CLL, including the landmark CLL14 trial of venetoclax plus obinutuzumab. His research program investigates MRD-guided treatment duration and sequencing of targeted agents. He has trained numerous CLL investigators and leads NCI-sponsored cooperative group CLL studies.